The global hospital infection therapeutics market was valued at US$ 14.4 Bn in 2017 and to Reach US$ 17.8 Bn by 2026; Market is projected to expand at a significant CAGR of 2.6% from 2019 to 2026. The global market is anticipated to witness relatively stable growth owing to expected pipeline therapeutics approvals and introduction of novel treatment approaches. Higher treatment cost of acute bacterial infections among the geriatric population due to longer hospital stays and difficulties in the treatment of these infections due to the presence of co-morbidities fuel the growth of the global hospital infection therapeutics market. Europe is expected to account for major share of the global hospital infection therapeutics market during the forecast period, owing to strong brand presence of major players with established distribution networks. The market in Asia Pacific is likely to expand at a significant CAGR from 2019 to 2026.
The report analyzes and forecasts the hospital infection therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of hospital infection therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major hospital infection therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of hospital infection therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of hospital infection therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global hospital infection therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the hospital infection therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of hospital infection therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Major players operating in the global hospital infection therapeutics market are Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company, among others.
The global hospital infection therapeutics market has been segmented as follows:
Global Hospital Infection Therapeutics Market, by Therapeutics
Global Hospital Infection Therapeutics Market, by Infection
Global Hospital Infection Therapeutics Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hospital Infection Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Therapeutics Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2019–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Regulatory Scenario by Region/globally
5.2.Pipeline Analysis
5.3.Reimbursement Scenario by Region/globally
5.4.Disease Prevalence & Incidence Rate globally with key countries
5.5.Healthcare Industry Overview
5.6.Value Chain Analysis
6. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Forecast, by Therapeutics, 2019–2026
6.3.1. Antibacterial Drugs
6.3.1.1. Cell Wall Synthesis Inhibitors
6.3.1.2. Protein Synthesis Inhibitors
6.3.1.3. Others
6.3.2. Antifungal Drugs
6.3.2.1. Caspofungin
6.3.2.2. Amphotericin B
6.3.2.3. Others
6.3.3. Antiviral Drugs
6.3.4. Others
6.4. Market Attractiveness, by Therapeutics
7. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Infection
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Forecast, by Infection, 2019–2026
7.3.1. Hospital Acquired Pneumonia
7.3.2. Urinary Tract Infections
7.3.3. Gastrointestinal Disorders
7.3.4. Bloodstream Infections
7.3.5. Surgical Site Infections
7.3.6. Other Hospital Infections
7.4. Market Attractiveness, by Infection
8. Global Hospital Infection Therapeutics Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Hospital Infection Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Forecast, by Therapeutics, 2019–2026
9.2.1. Antibacterial Drugs
9.2.1.1. Cell Wall Synthesis Inhibitors
9.2.1.2. Protein Synthesis Inhibitors
9.2.1.3. Others
9.2.2. Antifungal Drugs
9.2.2.1. Caspofungin
9.2.2.2. Amphotericin B
9.2.2.3. Others
9.2.3. Antiviral Drugs
9.2.4. Others
9.3. Market Forecast, by Infection, 2019–2026
9.3.1. Hospital Acquired Pneumonia
9.3.2. Urinary Tract Infections
9.3.3. Gastrointestinal Disorders
9.3.4. Bloodstream Infections
9.3.5. Surgical Site Infections
9.3.6. Other Hospital Infections
9.4. Market Forecast, by Country, 2019–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapeutics
9.5.2. By Infection
9.5.3. By Country
10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Forecast, by Therapeutics, 2019–2026
10.2.1. Antibacterial Drugs
10.2.1.1. Cell Wall Synthesis Inhibitors
10.2.1.2. Protein Synthesis Inhibitors
10.2.1.3. Others
10.2.2. Antifungal Drugs
10.2.2.1. Caspofungin
10.2.2.2. Amphotericin B
10.2.2.3. Others
10.2.3. Antiviral Drugs
10.2.4. Others
10.3. Market Forecast, by Infection, 2019–2026
10.3.1. Hospital Acquired Pneumonia
10.3.2. Urinary Tract Infections
10.3.3. Gastrointestinal Disorders
10.3.4. Bloodstream Infections
10.3.5. Surgical Site Infections
10.3.6. Other Hospital Infections
10.4. Market Forecast, by Country/Sub-region, 2019–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapeutics
10.5.2. By Infection
10.5.3. By Country/Sub-region
11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Forecast, by Therapeutics, 2019–2026
11.2.1. Antibacterial Drugs
11.2.1.1. Cell Wall Synthesis Inhibitors
11.2.1.2. Protein Synthesis Inhibitors
11.2.1.3. Others
11.2.2. Antifungal Drugs
11.2.2.1. Caspofungin
11.2.2.2. Amphotericin B
11.2.2.3. Others
11.2.3. Antiviral Drugs
11.2.4. Others
11.3.Market Forecast, by Infection, 2019–2026
11.3.1. Hospital Acquired Pneumonia
11.3.2. Urinary Tract Infections
11.3.3. Gastrointestinal Disorders
11.3.4. Bloodstream Infections
11.3.5. Surgical Site Infections
11.3.6. Other Hospital Infections
11.4.Market Forecast, by Country/Sub-region, 2019–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5.Market Attractiveness Analysis
11.5.1. By Therapeutics
11.5.2. By Infection
11.5.3. By Country/Sub-region
12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Forecast, by Therapeutics, 2019–2026
12.2.1. Antibacterial Drugs
12.2.1.1. Cell Wall Synthesis Inhibitors
12.2.1.2. Protein Synthesis Inhibitors
12.2.1.3. Others
12.2.2. Antifungal Drugs
12.2.2.1. Caspofungin
12.2.2.2. Amphotericin B
12.2.2.3. Others
12.2.3. Antiviral Drugs
12.2.4. Others
12.3.Market Forecast, by Infection, 2019–2026
12.3.1. Hospital Acquired Pneumonia
12.3.2. Urinary Tract Infections
12.3.3. Gastrointestinal Disorders
12.3.4. Bloodstream Infections
12.3.5. Surgical Site Infections
12.3.6. Other Hospital Infections
12.4.Market Forecast, by Country/Sub-region, 2019–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5.Market Attractiveness Analysis
12.5.1. By Therapeutics
12.5.2. By Infection
12.5.3. By Country/Sub-region
13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Forecast, by Therapeutics, 2019–2026
13.2.1. Antibacterial Drugs
13.2.1.1. Cell Wall Synthesis Inhibitors
13.2.1.2. Protein Synthesis Inhibitors
13.2.1.3. Others
13.2.2. Antifungal Drugs
13.2.2.1. Caspofungin
13.2.2.2. Amphotericin B
13.2.2.3. Others
13.2.3. Antiviral Drugs
13.2.4. Others
13.3.Market Forecast, by Infection, 2019–2026
13.3.1. Hospital Acquired Pneumonia
13.3.2. Urinary Tract Infections
13.3.3. Gastrointestinal Disorders
13.3.4. Bloodstream Infections
13.3.5. Surgical Site Infections
13.3.6. Other Hospital Infections
13.4.Market Forecast, by Country/Sub-region, 2019–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Therapeutics
13.5.2. By Infection
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2017)
14.3.Market Footprint Analysis
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Allergan
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Strategic Overview
14.5.1.5. Financial Overview
14.5.2. AstraZeneca
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Strategic Overview
14.5.2.5. Financial Overview
14.5.3. Basilea Pharmaceutica Ltd.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Strategic Overview
14.5.3.5. Financial Overview
14.5.4. Bayer AG
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Strategic Overview
14.5.4.5. Financial Overview
14.5.5. Bristol-Myers Squibb Company
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Strategic Overview
14.5.5.5. Financial Overview
14.5.6. F. Hoffman-La Roche Ltd.
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Strategic Overview
14.5.6.5. Financial Overview
14.5.7. GlaxoSmithKline plc.
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Strategic Overview
14.5.7.5. Financial Overview
14.5.8. Johnson & Johnson Services, Inc.
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Strategic Overview
14.5.8.5. Financial Overview
14.5.9. Merck & Co., Inc.
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Strategic Overview
14.5.9.5. Financial Overview
14.5.10. Pfizer Inc.
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Strategic Overview
14.5.10.5. Financial Overview
14.5.11. Sanofi
14.5.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.11.2. Product Portfolio
14.5.11.3. SWOT Analysis
14.5.11.4. Strategic Overview
14.5.11.5. Financial Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers